This database contains 15 studies, archived under the term: "Alzheimer's & Dementia: The Journal Of The Alzheimer's Association"
Click here to filter this large number of results.
Reducing dangerous nighttime events in persons with dementia by using a nighttime monitoring system
Rowe, Meredeth A.,
Kelly, Annette,
Horne, Claydell,
Lane, Steve,
Campbell, Judy,
Lehman, Brandy,
Phipps, Chad,
Keller, Meredith,
Pe Benito, Andrea
Background: Nighttime activity, a common occurrence in persons with dementia, increases the risk for injury and unattended home exits and impairs the sleep patterns of caregivers. Technology is needed that will alert caregivers of nighttime activity in persons with dementia to help prevent injuries and unattended exits. Methods: As part of a product development grant, […]
Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle Study: Collaboration with the Alzheimer’s Disease Neuroimaging Initiative
Ellis, Kathryn A.,
Rowe, Christopher C.,
Villemagne, Victor L.,
Martins, Ralph N.,
Masters, Colin L.,
Salvado, Olivier,
Szoeke, Cassandra,
Ames, David
The Australian Imaging Biomarkers and Lifestyle (AIBL) study is a longitudinal study of 1112 volunteers from healthy, mild cognitive impairment, and Alzheimer’s disease (AD) populations who can be assessed and followed up for prospective research into aging and AD. AIBL aims to improve understanding of the pathogenesis, early clinical manifestation, and diagnosis of AD, and […]
Diuretic use is associated with better learning and memory in older adults in the Ginkgo Evaluation of Memory Study
Yasar, Sevil,
Lin, Fu-Mei,
Fried, Linda P.,
Kawas, Claudia H.,
Sink, Kaycee M.,
DeKosky, Steven T.,
Carlson, Michelle C.
Background: To investigate the association between diuretics, angiotensin-converting enzyme inhibitors (ACE-I), angiotensin II receptor blockers (AT2RB), and cognitive function.; Methods: This post hoc analysis of the randomized controlled Ginkgo Evaluation of Memory Study trial focuses on 3069 nondemented community-dwelling participants aged >75 years. At baseline visit, detailed information about medication use was collected and five […]
Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
Farlow, Martin,
Arnold, Steven E.,
van Dyck, Christopher H.,
Aisen, Paul S,
Snider, B. Joy,
Porsteinsson, Anton P.,
Friedrich, Stuart,
Dean, Robert A.,
Gonzales, Celedon,
Sethuraman, Gopalan,
Demattos, Ronald B.,
Mohs, Richard,
Paul, Steven M.,
Siemers, Eric R.
Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti-β-amyloid (Aβ) antibody, in patients with mild-to-moderate Alzheimer’s disease. Cognitive measures were also obtained.; Methods: In this phase 2, randomized, double-blind, placebo-controlled clinical trial, 52 patients with Alzheimer’s disease received placebo or antibody (100 mg every 4 weeks, 100 […]
Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer’s disease
Weiner, Michael W.,
Sadowsky, Carl,
Saxton, Judith,
Hofbauer, Robert K.,
Graham, Stephen M.,
Yu, Sung Yun,
Li, Shaoyi,
Hsu, Hai-An,
Suhy, Joyce,
Fridman, Moshe,
Perhach, James L.
Background: This study was designed to assess changes in brain volume and cognitive abilities in memantine-treated patients with Alzheimer’s disease (AD) by using an exploratory, single-arm, delayed-start design.; Methods: Cholinesterase inhibitor-treated patients with AD (N = 47; Mini-Mental State Examination score range: 15-23) were enrolled in an observational lead-in period (weeks: 1-24), followed by an […]
Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.” The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer’s disease
Gillette-Guyonnet, Sophie,
Andrieu, Sandrine,
Dantoine, Thierry,
Dartigues, Jean-François,
Touchon, Jacques,
Vellas, B.
Background: Because no effective curative approaches are available, preventive approaches in the field of Alzheimer’s disease (AD) are needed. We present the design of the ongoing Multidomain Alzheimer Preventive Trial (MAPT) Study. Several previous studies suggested that many factors may be involved in the occurrence of AD at late ages. Because of the probable multifactorial […]
Extended results of the Alzheimer’s disease anti-inflammatory prevention trial
Breitner, John C.,
Baker, Laura D.,
Montine, Thomas J.,
Meinert, Curtis L.,
Lyketsos, Constantine G.,
Ashe, Karen H.,
Brandt, Jason,
Craft, Suzanne,
Evans, Denis E.,
Green, Robert C.,
Ismail, M. Saleem,
Martin, Barbara K.,
Mullan, Michael J.,
Sabbagh, Marwan,
Tariot, Pierre N.
Background: Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) delay onset of Alzheimer’s dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD. The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) randomized 2,528 elderly persons to naproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments […]
Activity loss is associated with cognitive decline in age-related macular degeneration
Background/methods: The objective of this study was to determine whether relinquishing cognitive, physical, and social activities is associated with an increased risk of cognitive decline in patients with age-related macular degeneration (AMD). We conducted a 3-year longitudinal study of 206 nondemented patients with AMD.; Results: Twenty-three subjects (14.4%) declined cognitively. Age, sex, education, decline in […]